Cargando…

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

In a previous proteomic study, we identified the neurosecretory protein VGF (VGF) as a potential biomarker for dementia with Lewy bodies (DLB). Here, we extended the study of VGF by comparing levels in cerebrospinal fluid (CSF) from 44 DLB patients, 20 Alzheimer’s disease (AD) patients, and 22 cogni...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Steenoven, Inger, Noli, Barbara, Cocco, Cristina, Ferri, Gian-Luca, Oeckl, Patrick, Otto, Markus, Koel-Simmelink, Marleen J. A., Bridel, Claire, van der Flier, Wiesje M., Lemstra, Afina W., Teunissen, Charlotte E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801397/ https://www.ncbi.nlm.nih.gov/pubmed/31547145 http://dx.doi.org/10.3390/ijms20194674

Ejemplares similares

Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach
por: van Steenoven, Inger, et al.
Publicado: (2020)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
por: Boiten, Walter A., et al.
Publicado: (2020)

Correction: Boiten et al. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells 2021, 10, 38
por: Boiten, Walter A., et al.
Publicado: (2022)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Disease progression in dementia with Lewy bodies: A longitudinal study on clinical symptoms, quality of life and functional impairment
por: van de Beek, Marleen, et al.
Publicado: (2022)

Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies
por: Chatterjee, Madhurima, et al.
Publicado: (2020)

Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies
por: van der Lee, Sven J., et al.
Publicado: (2021)

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
por: van de Beek, M., et al.
Publicado: (2020)

Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease
por: van de Beek, Marleen, et al.
Publicado: (2019)

EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology
por: van der Zande, Jessica J., et al.
Publicado: (2018)

Family History is Associated with Phenotype in Dementia with Lewy Bodies
por: Vergouw, Leonie J.M., et al.
Publicado: (2020)

VGF Changes during the Estrous Cycle: A Novel Endocrine Role for TLQP Peptides?
por: Noli, Barbara, et al.
Publicado: (2014)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Photoperiod Regulates vgf-Derived Peptide Processing in Siberian Hamsters
por: Noli, Barbara, et al.
Publicado: (2015)

Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
por: Rossi, Marcello, et al.
Publicado: (2021)

Optimizing cCOG, a Web‐based tool, to detect dementia with Lewy Bodies
por: van Gils, Aniek M., et al.
Publicado: (2022)

Profiles of VGF Peptides in the Rat Brain and Their Modulations after Phencyclidine Treatment
por: Noli, Barbara, et al.
Publicado: (2017)

VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
por: D’Amato, Filomena, et al.
Publicado: (2015)

Hypothalamic over-expression of VGF in the Siberian hamster increases energy expenditure and reduces body weight gain
por: Lewis, Jo E., et al.
Publicado: (2017)

Correction: Hypothalamic over-expression of VGF in the Siberian hamster increases energy expenditure and reduces body weight gain
por: Lewis, Jo E., et al.
Publicado: (2017)

Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results
por: van de Beek, M., et al.
Publicado: (2021)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies
por: Brancia, Carla, et al.
Publicado: (2016)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease
por: Dauwan, Meenakshi, et al.
Publicado: (2016)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023)

Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease and Vascular Dementia
por: Romani, Arianna, et al.
Publicado: (2020)

MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies
por: Inguanzo, Anna, et al.
Publicado: (2023)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
por: Hok‐A‐Hin, Yanaika S., et al.
Publicado: (2023)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

Neuroendocrine Role for VGF
por: Lewis, Jo E., et al.
Publicado: (2015)

Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort
por: Kleipool, Emma E.F., et al.
Publicado: (2019)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ra0oavnupmi7vqjqut9q6kub25